Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Co-Administration of 3 rd party Partially HLA Matched Cytomegalovirus Specific T Cells with Initial Antiviral Pharmacotherapy for Post-Transplant Viral Reactivation

Emily Blyth, B. MDHons), FRACP, FRCPA, PhD, Leighton Edward Clancy, PhD, Elissa Atkins, GIllian Huang, David Collins, David Bishop, Kenneth P. Micklethwaite, MBBS, PhD FRACP, FRCPA, David Gottlieb, MBBS, MD FRACP, FRCPA

Blood (2018) 132 (Supplement 1): 2051.

https://doi.org/10.1182/blood-2018-99-117417

Published: 2018

Journal Articles

3rd Party CMV-Specific T Cells Provide Long Term Protection Against Episodes of Recurrent CMV after Allogeneic Stem Cell Transplant Despite Lack of Persistence in Peripheral Blood

Emily Blyth, Barbara Withers, Leighton Edward Clancy, PhD, Agnes S. M. Yong, MDPhD, Christopher Fraser, MD, Jane Burgess, Renee Simms, Gloria Castellano Gonzalez, PhD, David Kliman, MBBS, Ming-Celine Dubosq, MD, David Bishop, Gaurav Sutrave, MBBS,, Chun Kei Kris Ma, PhDMBBS, Peter J. Shaw, MA,FRACP, Kenneth P. Micklethwaite, MBBS, PhD FRACP, FRCPA, David Gottlieb, MBBS, MD FRACP, FRCPA

Blood (2017) 130 (Supplement 1): 1919.

https://doi.org/10.1182/blood.V130.Suppl_1.1919.1919

Published: 2017

Journal Articles

Results of Using Automated Clinimacs Prodigy for CD34 Selection from Mobilized Peripheral Blood Stem Cell Products

Caroline M Bateman, MDPhDFRCPath, Vicki Antonenas, BSc, Kenneth Yehson, Daochen Tong, Gurdip Hansra, Leighton Edward Clancy, PhD, Peter J. Shaw, MA,FRACP, Kenneth P. Micklethwaite, MBBS, PhD FRACP, FRCPA, David Gottlieb, MBBS, MD FRACP, FRCPA

Blood (2017) 130 (Supplement 1): 3201.

https://doi.org/10.1182/blood.V130.Suppl_1.3201.3201

Published: 2017

Journal Articles

The Identification and Use of a Three Fungus-Antigen Combination to Generate T-Cell Products with Activity Against Pathogenic Filamentous Fungi and Yeasts for Clinical Cell Therapy

Shiva Deo, BSc PhD, Balaji Virassamy, M. Biotech, Catriona Halliday, PhD, Leighton Edward Clancy, PhD, Wieland Meyer, PhD, Sharon Chen, MB BS FRACP FRCPA PhD, Tania Sorrell, MB BS PhDFRACP FRCPA, David Gottlieb, MB MDFRCPA FRACP

Blood (2014) 124 (21): 3839.

https://doi.org/10.1182/blood.V124.21.3839.3839

Published: 2014

Journal Articles

Therapeutic Infusion of Partially HLA-Matched Third-Party Virus-Specific T Cells in HSCT Patients with Refractory Viral Infection

Leighton Edward Clancy, PhD, Emily Blyth, Barbara Withers, Jane Burgess, Renee Simms, Chun Kei Kris Ma, B.Sc (MD MB BS FRACP FRCPA, Kenneth P. Micklethwaite, MD PhD, David Gottlieb, MB MDFRCPA FRACP

Blood (2014) 124 (21): 3835.

https://doi.org/10.1182/blood.V124.21.3835.3835

Published: 2014

NARROW

Co-Administration of 3 rd party Partially HLA Matched Cytomegalovirus Specific T Cells with Initial Antiviral Pharmacotherapy for Post-Transplant Viral Reactivation

3rd Party CMV-Specific T Cells Provide Long Term Protection Against Episodes of Recurrent CMV after Allogeneic Stem Cell Transplant Despite Lack of Persistence in Peripheral Blood

Results of Using Automated Clinimacs Prodigy for CD34 Selection from Mobilized Peripheral Blood Stem Cell Products

The Identification and Use of a Three Fungus-Antigen Combination to Generate T-Cell Products with Activity Against Pathogenic Filamentous Fungi and Yeasts for Clinical Cell Therapy

Therapeutic Infusion of Partially HLA-Matched Third-Party Virus-Specific T Cells in HSCT Patients with Refractory Viral Infection

Email alerts

ASH Publications

American Society of Hematology

Co-Administration of 3 rd party Partially HLA Matched Cytomegalovirus Specific T Cells with Initial Antiviral Pharmacotherapy for Post-Transplant Viral Reactivation

3rd Party CMV-Specific T Cells Provide Long Term Protection Against Episodes of Recurrent CMV after Allogeneic Stem Cell Transplant Despite Lack of Persistence in Peripheral Blood

Results of Using Automated Clinimacs Prodigy for CD34 Selection from Mobilized Peripheral Blood Stem Cell Products

The Identification and Use of a Three Fungus-Antigen Combination to Generate T-Cell Products with Activity Against Pathogenic Filamentous Fungi and Yeasts for Clinical Cell Therapy

Therapeutic Infusion of Partially HLA-Matched Third-Party Virus-Specific T Cells in HSCT Patients with Refractory Viral Infection

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only